Recently, studies regarding age-related immunogenicity of COVID-19 vaccines echoed our results, showing that serum neutralization, binding IgG or IgA levels, and T cell responses were more robust in younger adults after the first dose [22,30,31]. This evidence concerns the gene CD79A and COVID-19.